The nation of Zimbabwe has declined a major American health deal valued at $367m (272 million pounds) over five years because of the United States' insistence on confidential biological samples.
This rejection came to light after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson later stated that the US was demanding access to genetic material for scientific study and commercial gain while refused to share the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for more dialogue to reach a agreement acceptable to all parties so the nation's vital HIV programme can be sustained.
Wider Context
This development follows a similar situation in Kenya, where a court suspended a related health funding agreement following concerns were raised about the safety of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government agreements to enhance transparency and accountability.
According to statements, Sixteen nations in Africa have to date agreed to similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
This assistance for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any equivalent promise of benefiting from any medical innovations – like new medicines or tests – that might result from that provided information," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the final treatments would be accessible to our population if a new pandemic arise."
Sovereignty and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its push of bilateral deals were disrupting systems already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," he added.
"We welcome further discussions with our US partners on how future co-operation might be designed in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that negotiations must proceed considering a large portion of the nation's HIV programmes depended on external financing.
"Where technical issues arise, such as those relating to data governance or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it added.
The situation highlights the continuing tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more interconnected world.